Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial
Pooled result · Percentage of body weightResult — go to the resultMD −11.80 % 95% CI −12.93 to −10.68Authors' conclusion
In overweight or obese non-diabetic individuals, semaglutide had a remarkable and sustained weight loss effect that was well tolerated and safe.
Study context
- Population
- Non-diabetic overweight or obese adults; databases searched from inception to April 11, 2023
- Participants
- 3,962 participants6 randomized controlled trials (RCTs)
- Comparison
- Once-weekly SC semaglutide 2.4 mg vs placebo
- Outcome
- Percentage of body weight
Pooled result
As reported in the abstract
MD
−11.80 %
95% CI −12.93 to −10.68
P < 0.00001
Semaglutidevs Placebo
MD −11.80 % (95% CI −12.93 to −10.68); P < 0.00001
Further pooled results
| Outcome | MD (kg) (95% CI) | P value | |
|---|---|---|---|
| Absolute body weight | −12.2 (−13.3 to −11.1) | P < 0.00001 | |
| −20−10010Difference, kg (linear scale) |
| Outcome | MD (kg/m²) (95% CI) | P value | |
|---|---|---|---|
| BMI | −4.5 (−4.9 to −4.1) | P < 0.00001 | |
| −6−4−202Difference, kg/m² (linear scale) |
| Outcome | MD (cm) (95% CI) | P value | |
|---|---|---|---|
| Waist circumference | −9.4 (−10.1 to −8.8) | P < 0.00001 | |
| −15−10−505Difference, cm (linear scale) |
Weight loss >5%, 10%, 15% and 20%
- Higher proportion of patients with weight loss exceeding 5%, 10%, 15% and 20% with semaglutide
Blood pressure, blood sugar, C-reactive protein and lipids
- Semaglutide showed significant efficacy in controlling blood pressure, blood sugar, C-reactive protein and lipid profiles
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Gastrointestinal adverse reactions | 1.49 (1.38–1.60) | P < 0.00001 | |
| 0.512Relative risk (log scale) |
Gastrointestinal adverse reactions
- Most common adverse effects; generally mild to moderate and temporary
Original publication
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial. Diabetes Obes Metab. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →